- 07/30/2020
- application for additional indication of anti cancer agent lenvima® for unresectable thymic carcinoma submitted in japan
- 07/28/2020
- eisai and dena to provide smartphone app “easiit app” through business alliance agreement
- 07/20/2020
- smartphone app for vital signs measurement of patients with the novel coronavirus infection experimental study project adopted as amed project
- 07/14/2020
- initiation of new phase iii clinical study (ahead 3-45) of ban2401 preclinical (asymptomatic) alzheimer’s disease
- 07/10/2020
- industry-academia-government joint development agreement aiming for drug discovery for systemic lupus erythematosus by practical application of toll-like receptor research concluded
- 07/06/2020
- new fine granule formulation of anti-epileptic drug fycompa® launched in japan
- 06/25/2020
- eisai receives approval for parkinson’s disease treatment equfina® in south korea
- 06/02/2020
- eisai launches new insomnia drug dayvigo™ (lemborexant) civ in the united states as a treatment option for adults with insomnia
- 05/29/2020
- abbvie and eisai announce an approval for partial changes in the marketing approval of humira®, a fully human anti-tnfα monoclonal antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa
- 05/14/2020
- eisai to present data on oncology pipeline and products at asco annual meeting
